Orum Therapeutics
20 Acorn Park Drive
Suite 501
Cambridge
MA
02140
United States
Website: http://www.orumrx.com/
Email: contact@orumrx.com
About Orum Therapeutics
Orum Therapeutics is a private biotech company located in Cambridge, Massachusetts, US and Daejeon, Korea. We are developing a novel class of therapeutics to bring new medicines to patients with unmet medical needs. Orum leverages its proprietary antibody-drug conjugate platforms to inhibit or degrade intracellular target proteins. We are advancing our first set of oncology candidates toward preclinical development.
18 articles with Orum Therapeutics
-
Orum Therapeutics Announces Three Presentations at AACR 2023
3/14/2023
Orum Therapeutics, Inc. announced that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research Annual Meeting 2023 taking place April 14-19 in Orlando.
-
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022
12/10/2022
Orum Therapeutics announced the presentation of positive preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia, at the 64th American Society of Hematology Annual Meeting & Exposition taking place December 10-13 in New Orleans and virtually.
-
Orum Therapeutics Announces Presentation at ASH 2022 Annual Meeting
11/3/2022
Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML).
-
Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors
10/31/2022
Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first patient has been dosed with ORM-5029 in a Phase 1 clinical trial for patients with HER2-expressing advanced solid tumors.
-
Orum Therapeutics to Participate at Investor Conferences in September
9/6/2022
Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Company’s leadership will participate in the following investor conferences.
-
Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
4/8/2022
Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today presented preclinical data for ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancers, at the American Association for Cancer Research (“AACR”) Annual Meeting 2022.
-
Orum Therapeutics Announces Formation of Scientific Advisory Board
4/4/2022
Orum Therapeutics today announced the formation of its scientific advisory board (SAB).
-
Orum Therapeutics Appoints David Main to Board of Directors
3/23/2022
Orum Therapeutics today announced the appointment of David Main to the Company’s Board of Directors.
-
Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022
3/8/2022
Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company will present preclinical data for ORM-5029 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 taking place April 8-13 virtually and in-person at the Ernest N. Morial Convention Center in New Orleans.
-
Orum Therapeutics to Participate in February 2022 Investor Conferences
2/10/2022
Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, announced that the Company’s leadership will participate in the following virtual conferences.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Orum Therapeutics Appoints Olaf Christensen, M.D., as Chief Medical Officer
10/6/2021
Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, today announced the appointment of Olaf Christensen, M.D., as Chief Medical Officer.
-
Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer
6/23/2021
Orum today announced the close of a $84 million Series B financing.
-
Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics
7/17/2019
Financing proceeds to fund further platform development and therapeutic discovery in cancer and rare diseases, and expansion of Orum’s new Boston R&D labs
-
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
-
Orum Therapeutics Raises $8 Million Series A Financing To Advance Cell-Penetrating Antibody Technology For Novel Cancer Therapeutics
6/14/2017
-
Orum Therapeutics Release: Cell-Penetrating Antibodies To Oncogenic RAS Show Anti-Tumor Activity
5/10/2017
-
Orum Therapeutics Selected For South Korea's Prestigious Tech Incubator Program For Startup
12/21/2016